新疆维吾尔族、汉族缺血性脑血管疾病磷酸二酯酶4D基因SNP83多态性研究
|
摘要
目的：探讨新疆地区维吾尔族(以下简称维族)、汉族磷酸二酯酶4D基因(phosphodiesterase 4D, PDE4D) SNP83多态性与缺血性脑血管疾病(Ischemic cerebral vascular disease, ICVD)的关系。方法：选取新疆部分地区缺血性脑血管疾病患者207例(维吾尔族109例,汉族98例)与正常对照组216例(维吾尔族110例,汉族106例),应用聚合酶链反应-限制性片段长度多态性技术检测PDE4D基因SNP83位点多态性,采用病例-对照的关联分析方法进行基因型和等位基因频率分布。结果：1)PDE4D基因SNP83的基因型在病例组(维族x2=0.028,P>0.05;汉族x2=1.945,P>0.05)和对照组(维族x2=4.555,P>0.05；汉族x2=8.690,P>0.05)中均符合Hardy-Weinberg平衡定律；2)新疆维、汉两民族PDE4D基因SNP83的基因型和等位基因频率在病例组与对照组间的分布差异有统计学意义(P<0.05)；3)新疆维、汉两民族间比较,PDE4D基因SNP83的基因型和等位基因频率在病例组与对照组间的分布差异有统计学意义(P<0.05)。在汉族人群中病例组与对照组的基因型和等位基因分布频率差异有统计学意义(P<0.05)。且在汉族携带C等位基因个体发生缺血性脑血管疾病的危险性高于携带T等位基因个体,其OR值为2.679(P<0.05)。而在维族人群中病例组与对照组间基因型频率和等位基因频率分布差异无统计学意义；4)按性别进行分层,男性病例组中PDE4D基因SNP83基因型分布频率和等位基因频率显著高于男性对照组(P<0.05),并发现携带C等位基因的个体发生缺血性脑血管疾病的危险性显著增加,其OR值为6.486(P<0.05)。而在女性病例组与女性对照组间基因型频率和等位基因频率分布差异无统计学意义;5)按照有无高血压病史进行分层,在无高血压病史ICVD组与对照组PDE4D基因SNP83位点基因型和等位基因频率分布差异无统计学意义(P>0.05)；而在有高血压病史ICVD组与对照组PDE4D基因SNP83位点基因型和等位基因频率分布差异有统计学意义(P<0.05),并发现伴高血压病史携带C等位基因的个体发生ICVD的危险性显著增加,其OR值为5.202(P<0.05)。而无高血压病史ICVD组与对照组PDE4D基因SNP83位点基因型和等位基因频率分布差异无统计学意义,未发现携带C等位基因的个体发生ICVD的危险性增加。结论：新疆维吾尔族和汉族之间PDE4D基因SNP83多态性存在差异,并发现在汉族、同时伴有高血压病史及男性人群中PDE4D基因SNP83多态性与缺血性脑卒中的发病风险存在关联。
Objective:To investigate the relationship of the PDE4D gene SNP83 polymor-phisms and ICVD between Uygurs and Hans population in Xinjiang. Methods:207 ICVD patients (98Hans,109Uygurs) and 216 healthy controls (99 Hans,110 Uygurs) are collected in xinjiang.The polymorphism of the PDE4D gene were determined by the PCR-restriction fragment length polymorphism technique. The case-control analysis was adopted to analyze the frequencies of genotypes and alleles. Results:1) The genotypes of PDE4D gene were consistent with Hardy-Weinberg equilibrium in both ICVD group (Uygurs:χ2=0.028, P>0.05 Han:χ2=1.945, P>0.05) and control group (Uygurs:χ2=4.555, P>0.05 Han:，χ2=8.69, P>0.05).2) There is statistical difference in the distribution of genotypes and allele frequency of PDE4D gene between ICVD group and control group (P<0.05).3) Divided by nation, the frequencies of CC genotype and C allele in Han patients is higher than that in Han controls (P<0.05), which has statistical difference; while there is no statistical difference in the distribution of the genotypes and allele frequency between Uygur's ICVD group and control group.4) Divided by sex, the frequencies of genotypes and alleles of the PDE4D gene in male patients are higher than that in male controls (P<0.05), and the male individual carrying the C allele has a notably increasing occurrence of ICVD (OR=6.486, P<0.05); while there is no statistical difference in the distribution of genotypes and allele frequency between female-ICVD group and female-control group.5) Divided by the history hypertension, the distribution of genotypes and allele frequency of the PDE4D gene has statistical difference between the ICVD group who have the history of hypertension and the control group who have the history of hypertension (P<0.05), and the individual carrying C allele among them has a notably increasing occurrence of ICVD (OR=5.202,P<0.05); while there is no statistical difference in the distribution of genotypes and allele frequency between ICVD group who have no the history of hypertension and control group who have no the history of hypertension. Conclusion:PDE4D gene SNP83 polymorphisms have statistical differences between Chinese XinJiang Uygurs and Hans population.There might be an association between PDE4D gene SNP83 polymorphisms and the morbidity risk of ICVD among the population, who are Hans, or who are male, who have the history of hypertension.
Objective:To investigate the relationship of the PDE4D gene SNP83 polymor-phisms and ICVD between Uygurs and Hans population in Xinjiang. Methods:207 ICVD patients (98Hans,109Uygurs) and 216 healthy controls (99 Hans,110 Uygurs) are collected in xinjiang.The polymorphism of the PDE4D gene were determined by the PCR-restriction fragment length polymorphism technique. The case-control analysis was adopted to analyze the frequencies of genotypes and alleles. Results:1) The genotypes of PDE4D gene were consistent with Hardy-Weinberg equilibrium in both ICVD group (Uygurs:χ2=0.028, P>0.05 Han:χ2=1.945, P>0.05) and control group (Uygurs:χ2=4.555, P>0.05 Han:，χ2=8.69, P>0.05).2) There is statistical difference in the distribution of genotypes and allele frequency of PDE4D gene between ICVD group and control group (P<0.05).3) Divided by nation, the frequencies of CC genotype and C allele in Han patients is higher than that in Han controls (P<0.05), which has statistical difference; while there is no statistical difference in the distribution of the genotypes and allele frequency between Uygur's ICVD group and control group.4) Divided by sex, the frequencies of genotypes and alleles of the PDE4D gene in male patients are higher than that in male controls (P<0.05), and the male individual carrying the C allele has a notably increasing occurrence of ICVD (OR=6.486, P<0.05); while there is no statistical difference in the distribution of genotypes and allele frequency between female-ICVD group and female-control group.5) Divided by the history hypertension, the distribution of genotypes and allele frequency of the PDE4D gene has statistical difference between the ICVD group who have the history of hypertension and the control group who have the history of hypertension (P<0.05), and the individual carrying C allele among them has a notably increasing occurrence of ICVD (OR=5.202,P<0.05); while there is no statistical difference in the distribution of genotypes and allele frequency between ICVD group who have no the history of hypertension and control group who have no the history of hypertension. Conclusion:PDE4D gene SNP83 polymorphisms have statistical differences between Chinese XinJiang Uygurs and Hans population.There might be an association between PDE4D gene SNP83 polymorphisms and the morbidity risk of ICVD among the population, who are Hans, or who are male, who have the history of hypertension.
引文
[1]王维治.神经病学[M].北京：人民卫生出版社,第5版.2006年：126-126
[2]李忠.缺血性脑血管疾病[M].北京：科学技术出版社,2002
[3]Gillum RF. The epidemiology of stroke in Native Americans[J]. Stroke,1995, 26:514-521
[4]Thom TJ. Stroke mortality trends:an international perspective[J]. Ann Epidemiol, 1993,3:509-518
[5]Lanska DJ. Geographic distribution of stroke mortality in the united states:1939-1941 to 1979-1981[J]. Neurology,1993,43:1839-1851
[6]HollowayRG, WitterDMJr, LawtonKB, et al. Inpatient costs of specific cerebrovascular events at five academic medical centers[J]. Neurology,1996, 46:854-860
[7]王文志.应高度重视和加强对脑卒中的一级预防[J].中国现代神经疾病杂志,2006,6(1)：1-2.
[8]王化文,赵冬,吴桂贤.等.北京市1984-1999年人群脑卒中发病率变化趋势分析[J].中华流行病学杂志,2001.22：269-272
[9]李振三,杨期东,苏启庚,等.我国脑卒中的地理分布[J].中华神经外科杂志,1989.5增刊：11-14
[10]谢财忠,唐军凯脑血管疾病的多重危险因素：研究与进展[J].中国临床康复2004,8(34)：7765-7767
[11]孙文萍 黄强 万琪 脑血管病的遗传研究现况[J].国外医学神经病学神经外科学分册2002,29(2)：125-128
[12]蒲传强,郎森阳,吴卫平.脑血管病学.人民军医出版社,1999,第一版,166-167
[13]Brass L, Isaacsohn J, Merikangas K, et al. Steady of twiws and strike[J]. Stroke. 1992,23:221-223.
[14]Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke[J]. Stroke,2004,35:212-227
[15]Graffagnino C, Gseck A, Doing G, et al. The importance of family history in cereb-rovascular disease[J]. Stroke.1994,25:1599～1604
[16]Brass L, Isaacsohn J, Merikangas K, et al. Steady of twiws and strike[J]. Stroke. 1992,23:221-223
[17]Couderc R, Mahieux F, Balilleul S, Fenelon G, Mary R, Fermanian J. Prevalence of apolipoprotein E phenotypes in ischemic cerebrovscular disease：a case-control study[J]. Stroke,1993,24:661-664
[18]Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease[J]. Blood,2000,95(5):1517-1531
[19]Yoshida H, Imaizumi T, Fujimoto K. A mutation in plasma platelet-activating factor acetylhydrolase(Va1279-Phe)is a genetic risk factor for cerebral hemorrhage but not for hypertention[J]. Thromb Haemost,1998,80(3):372-375
[20]Perry LJ. Homocysteine and risk of stroke[J]. J Cardiovasc Risk,1999,6(4):235-240.
[21]Perna AF, Castaldo P, Ingrosso D. Homocysteinc, a new cardiovascular risk factor, is also a powerful uremic toxin[J]. J nephrol,1999,12(4):230-240
[22]Fle A, Gaetani E, Papaleo P, et al. Proin ammatory genetic proles insubjects with history of ischemic stroke[J]. Stroke,2004,35:2270-2275
[23]Greisenegger S, Endler G, Haering D, et al. The(174)G/C polymorphism in the interleukin-6 gene is associated with the severity of acute cerebrovascularevents[J]. Thromb Res,2003,110:181-186
[24]Bulut D, Potthast R, Haneefld C, et al. ImPaired vasodilator responses to atrial natriuretic peptide in essential hypertension[J]. Eur J Clin invest,2003, 33(7):567-573
[25]王亚萍,牛小麟.基因多态性的研究方法及其临床应用[J].临床医学,2003,23(9)：49-50
[26]Gretarsdottir S, Thorleifsson G, Reynisdottir ST, et al. The gene encoding phospho-diesterase 4D confers risk of ischemic stroke[J]. Nat Genet,2003,35:131-138
[27]张颖冬.2006年卒中遗传学研究进展[J].中国卒中杂志,2007,2：136-139
[28]Kostic MM, Erdogan S, Rena G, et al. Altered expression of PDE1 and PDE4D cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin preconditioned rat heart[J]. J Mol Cell Cardiol,1997,29:3135-3146
[29]Houslay MD, Adams DR, PDE4 cAMP phosphodiesterase:modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization[J]. Biochem J,2003,370:1-18
[30]Shepherd MC, Baillie GS, StirlingD I, et al. Remodelling of the PDE4 cAMP phosphodiesterase isoform p rofile upon monocyte2macrophage differentiation of human U937 cells[J]. Br J Pharmacol,2004,142:339-351
[31]Le Jeune IR, ShepherdM, Van Heeke G, et al. Cyclic AMP2dependent transcrip tional up2regulation of phosphod2 iesterase 4D5 in human airway smooth muscle cells. Iden-tification and characterization of a novel PDE4D5 promoter[J]. J Biol Chem, 2002,277:35980-35989
[32]Wang D, Deng C, Bugaj2Gaweda B, et al. Cloning and characterization of novel PDE4D isoforms PDE4D6 and PDE4D7[J]. Cell Signal,2003,15:883-891
[33]中华神经科学会中华神经外科学会.各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29：379-380
[34]Chow dhury AH, Yokoyama T, Kokubo Y, et al. ApolipoproteinE genet ic polymorph ism and st roke subt ypes in a Bangladeshi hospital based study[J]. Epidemiol,2001, 11(3):131-138
[35]Kokubo Y, Chow dhury AH, Dat e C, et al. Age dependent associaton of apolipoprotein E genot ypes w ith stroke subt ypes in a Japanese rural population[J]. Stroke,2000,31(6):1299-1306
[36]Jin ZQ, Fan YS, Ding J, et al. Association of apolipoprotein E4 polymorphism w- ith cerebral infarction in Chinese Han population[J]. Act a Pharmacol Sin,2004, 25(3):352-356
[37]Um JY, Moon KS, Lee KM, et al. Polymorphism of angiotensin converting enzyme, angiot ensinogen, and apolipoprotein E genes in Korean patients with cerebral infarction[J]. Mol Neurosci,2003,21(1):23-28
[38]Okamoto K, Takai S, Sasaki S, et al. Trandolapril reduces infarction area after middle cerebral artery occlusion in rats[J]. Hypertens Res,2002,25:583- 588
[39]Morisaw a T, Kishimot o Y, Kitano M, et al. Inf luence of angiotensin type 1 receptor polymorphism on hypertension in patients with hyperchdolest erolemia[J]. Clin Chim Act a,2001,304:91- 97
[40]Aalt o K, Palomzi H, Miett inen H. Genetic risk factors and ischemic cerebrovacular disease:role of common varivation of the genes endoing apolipoprot- eins and angiotensin converting enzyme[J]. Ann Med,1998,30(2):224
[41]Catto A, Barrett H, Angiot ensin-converting enzyme insertion deletion polymorphism and cerebrovascular disease[J]. Stroke,1998,27:435
[42]Baroni MG, Berni A, Romeo S, et al. Genetic study of common variants at the Apo E, ApoAⅠ, ApoCⅢ, ApoB, lipoprotein lipase(LPL)and hepatic lipase(LIPC)genes and coronary artery disease(CAD):variation in LIPC gene associates with clinical out comes in patients with established CAD[J]. BMC Med Genet,2003,4:8
[43]Shimo- Nakanishi Y, Urabe T, Hat tori N, et al. Polymorphism of the lipoprotein lipase gene and risk of atherothrombotic cerebral infarction in the Japanese[J]. St -roke,2001,32:1481- 1486
[44]Moennig G, Wiebusch H, Enbergs A, et al. Detection of missense mutations in th -e genes for lipoprotein lipase and hepatic triglyceride lipase in patients with dys lipidemia undergoing coronary angiogra- phy[J]. Athcrosclerosis,2000,149:395-401
[45]Spence JD, Ban MR, Hegele RA. Lipoprot einlipase(LPL)gene variation and progression of carotid artery plaque[J]. S troke,2003,34:1176-1180
[46]Wittrup HH, Nordestgaard BG, Sillesen H, et al. A common mutation in lipoprot einlipase confers a 2-fold increase in risk of ischemic cerebrovascular disease in w-omen but not in men[J]. Circulation.2000,101:2393- 2397
[47]Morrison AC, Ballantyne CM, Bray M, et al. LPL polymorphism predicts stroke risk in men[J]. Genet Epidemiol,2002,22:233- 242
[48]Pras H, Philip H, Nitricoxide as modulat or of function[J]. Prog Neuronal,2004, 64:51- 68
[49]Dudzinski DM, Lgarashi J, Greif D, et al. The regulation and pharmacology enclothelial nitricoxide synthase[J]. Annu Rer Pharmacol Toxicol,2006,46:235- 276
[50]Hou L, Osei Hyiaman D, Yu H, et al. Association of a 27- bp repeat polym -orphism in eNOS gene with ischemic stroke in Chinese patients[J]. Neurology,2001, 56(4):490- 496
[51]Elbaz A, Poirier O, Moulin T, et al. Associatition between the Glu298Asp polymorphism in the endothelial constitutive nitric oxide synthase gene and brain in farction.[J]. St roke,2000,31(7):1634- 1639
[52]马学玲,王晓明,张桂茹,等.β纤维蛋白原基因Bcl2I多态性与血浆纤维蛋白原水平及脑梗死相关性研究[J].中国实验诊断学,2006,10(2)：153-155
[53]赵伟佳,杨和平,沈岳飞,等.脑梗死患者纤维蛋白原、血液流变学动态变化与β2纤维蛋白原基因2455G/A多态性的关系[J].中国临床康复,2005,9(5)：94-96
[54]李永杰,霍阳,高旭光,等.纤维蛋白原β基因148C/T及亚甲基四氢叶酸还原酶基因677C/T多态性与脑梗死的关系研究[J].中国神经免疫学和神经病学杂志,2005,12(6)：363-368
[55]唱浩,曹晓伟,侯迎秋,等.纤维蛋白原Bβ链2854G/A、Bcl21B1/B2基因多态性与脑梗死类型关系研究[J].临床荟萃,2005,20(22)：1268-1272
[56]Giacconi R, Cipriano C, Aibanese F, et al. The-174G/C polymorphism of IL-6 is useful to screen old subjects at risk for atherosclerosis or to reach successful ageing[J]. Exp Geront ol,2004,39:621- 628
[57]Bruunsgaard H, Christitmsen L, Pedcrsen AN, et al. The IL- 6- 174G>C polymorphism is associated with cardiovascular diseases and mortality in 80-years old humans[J]. Exp Gerontol,2004,39:255- 261
[58]宋冬晶,陈家俊,邬英全,等.IL-6 基因多态性与短暂性脑缺血发作的关系[J].吉林大学学报(医学版),2005,31(6)：924-926
[59]郭淮莲,蔡转,于步润.梗塞与HLA2 Ⅰ、Ⅲ单体型关联性初步研究[J].同济医科大学学报,1994,23(4)：280-283
[60]MeCann S K, Dusting G J, Roulston C L. Early increase of Nox4 NADPH oxidase and super oxide generation following endothelin-1-induced stroke in conscious rats[J]. J N eurosc(?) Res,2008,86(11):2524-2534
[61]杨惠玲.高级病理学[M].北京：科学出版社,1998：24-38
[62]先雄斌,袁琼兰.缺血性脑血管病的研究进展[J].海南医学,2008,19(1)：131-134
[63]Terao Y, Ohta H, Oda A, et al. Macrophage inflammatory protein-3alpha plays a key role in the inflammatory cascade in rat focal cerebral ischemia[J], N eurosci Res, 2009,64(1):75-82
[64]Dai H B, Fu Q L, ShenY, et al. The histamine H3 receptor antagonist clobenp rop it enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons[J]. Eur J Pharm-acol,2007,563(1/3):117-123
[65]Kilic E, Kilic U, Matter CM, et al. Aggravation of Focal Cerebral Ischemia by Tissue Plasminogen Activator Is Reversed by 32Hy2 droxy232Methylglutaryl Coenzyme A Reductase Inhibitor but Does Not Depend on Endothelial NO Synthase[J].Stroke, 2005,36(2):332-336
[66]MacManus JP, Linnik MD.Gene expression induced by cerebral ischemia:anapoptotic perspective[J]. Cereb Blood Flow Metab,1997,17(8):815-832. 26(7);1252-1258
[67]Sharp FR, Lu A, Tang Y, et al. Multiple molecular penumbras after focal cerebral ischemia[J]. J Cereb Blood FlowMetab,2000,20:10-11
[68]Hossmann, KA. Periin farct depolarizations. Cerebrovasc[J]. Brain Metab. Rev, 1996(8):195-208
[69]Mies G, Iijima T, Hossmann KA. Correlation between peri-infarct DC shifts and ischaemic neuronal damage in rat[J]. Neuroreport,1993, (4):709-711
[70]Gretarsdottir S, Sveinbjomsdottir S, Jonsson HH, et al. LocaliZation of a susceptibility gene for common forms of stroke to 5q12[J]. Am J Hum Genet,2002, 70:593-603
[71]Gretarsdottir S, Sveinbjomsdottir S, Thorleifsson G, Reynisdottir ST, et al. The gene encording phosphodiesterase 4D confers risk of ischemic stroke[J]. Nat genet,2003, 35:131-138
[72]Wang H, Robinson H, Ke H[J]. J Mol Biol,2007,302:371
[73]Souness JE. Immunopharmaeology[M],2000,47:127
[74]Bumouf Pruniaux. Current Pharmaceutical Design[M],2002,8:12-55
[75]Houslay MD, Schafer P, Zhang KY. Drug Discover Today[M],2005,101:503
[76]Houslay MD. Prog Nucleic Acids [J].ResMol Biol,2001,69:249.
[77]徐淑兰,张颖冬.磷酸二酯酶4D基因与缺血性脑血管病的研究进展[J].中国脑血管病杂志,2008,139-142
[78]Song Q, Cole JW, O'Connell JR, et al.12Phosphodiesterase 4D polymorphisms and the risk of cerebral infarction in a biracial population:the Stroke Prevention in young Women Study[J]. Hum Mol Genet,2006,15:2468-2478
[79]Saleheen D, Bukhari S, Haider SR, et al.3Association of phosphodiesterase 4D gene with ischemic stroke in a Pakistani population[J]. Stroke,2005,36:2275-2277
[80]Banerjee I, Grupta V, Ahmed T, et al. Inflammatory system gene polymorphism and the risk of stroke:A case-control study in an Indian population[J]. Brain Res Bull, 2008,75:158-165
[81]Nakayama T, Asai S, Sato N, et al.8 Genotype and haplotype association study of the STRK1 region on 5q12 among Japanese:a case-control study[J]. Srtoke,2006, 37:69-76
[82]Song Q, Cole JW, OpConnell JR, et al. Phosphodiesterase 4D poly-morphisms and the risk of cerebral infarction in a biracial population:the stroke prevention in young women study[J]. Hum Mol Genet,2006,15:2468
[83]曹军,洪震,黄茂盛,等.上海脑卒中急性期死亡的流行病学研究[J].中国临床神经科学,2001,9(4)：338-340
[84]徐淑兰,磷酸二酯酶4D基因多态性与缺血性脑血管病的关系[J].临床神经病学杂志,2008,04：249-252
[85]Willoughby D, WongW, Schaack J. Phosphodiesterase 4D poly-morphisms and the risk of cerebral infarction in a biracial population[J]. EMBO J,2006,25:51.
[86]Meschina JF, Brott TG, Brown RD J r, et al. Inflammatory system gene polymorphism and the risk of stroke [J].Ann Neurol,2005,51:58
[87]Woo D, Kaushal R, Kissela B, et al. phosphodiesterase 4D poly-morphisms and the risk of cerebral infarction in a biracial population[J].Stroke,2006,37:41
[88]徐波,邓春艳,张彩英.医药世界[M].2007,2：55
[89]谢财忠,唐军凯 脑血管疾病的多重危险因素：研究与进展[J].中国临床康复2004,8(34)：7765-7767
[90]全军脑血管病流调协作组.全国脑血管病学术座谈会论文专辑[C].1990.45-39
[91]李茂文,邓剑.脑栓塞患者血脂、高低密度脂蛋白载脂蛋白A、B的观察[J].卒中与神经疾病,1998,5(3)：162-164
[1]李忠.缺血性脑血管疾病[M].此京：科学技术出版社,2002：126-1 30
[2]王文志.应高度重视和加强对脑卒中的一级预防.中国现代神经疾病杂志[J].2006,6(1)：1-2
[3]Brass L, Isaacsohn J, Merikangas K, et al. Steady of twiws and strike[J]. Stroke. 1992,23:221-223
[4]Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke[J]. Stroke,2004,35:212-227
[5]Graffagnino C, Gseck A, Doing G, et al. The importance of family history in cereb-rovascular disease[J]. Stroke.1994,25:1599～1604
[6]Brass L, Isaacsohn J, Merikangas K, et al. Steady of twiws and strike[J]. Stroke. 1992,23:221-223
[7]Couderc R, Mahieux F, Balilleul S, Fenelon G, Mary R, Fermanian J. Prevalence of apolipoprotein E phenotypes in ischemic cerebrovscular disease:a case-control study[J]. Stroke,1993,24:661-664
[8]Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease[J]. Blood,2000,95(5):1517-1531
[9]Yoshida H, Imaizumi T, Fujimoto K. A mutation in plasma platelet-activating factor acetylhydrolase(Val279-Phe)is a genetic risk factor for cerebral hemorrhage but not for hypertention[J]. Thromb Haemost,1998,80(3):372-375
[10]Perry LJ. Homocysteine and risk of stroke[J]. Cardiovasc Risk,1999,6(4):235-240
[11]Perna AF, Castaldo P, Ingrosso D. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin[J]. J nephrol,1999,12(4):230-240
[12]Fle A, Gaetani E, Papaleo P, et al. Proin ammatory genetic proles insubjects with history of ischemic stroke[J]. Stroke,2004,35:2270-2275
[13]Greisenegger S, Endler G, Haering D, et al. The(174)G/C polymorphism in the interleukin-6 gene is associated with the severity of acute cerebrovascularevents[J]. Thromb Res,2003,110:181-186
[14]Cobbs CS, chen J, Greenberg DA, et al. Vascular endothelial growth factor expression in transient focal cerebral ischemia in the rat[J]. Neurosci Lett,1998, 249:79-82
[15]Markus HS, Alberts MJ. Update on genetics of stroke and cerebrovascular disease 2005[J]. Stroke,2006,37:288-290
[16]Gretarsdottir S, Thorleifsson G, Reynisdottir ST, et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke[J]. Nat Genet,2003, 35:131-138
[17]张颖冬.2006年卒中遗传学研究进展[J].中国卒中杂志,2007,2：1362139
[18]Soderiing SH, Bayuga SJ, Beavo JA. Isolation and characterization of a dual-substrate Phosphodiesterase gene family:PDE10A[J]. Pro Natl Acad SciUSA, 1999,96:7071-7076
[19]Beavo JA, Reifsnyder DH. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors[J]. Trends pharmacol Sci,1990, 11:150-155
[20]Fisher DA, smith JF, Pillar JS, et al. Isolation and characterization of PDE4A a novel human cAMP-specific phosphodiesterase[J]. Biochem Biophys Res Common,1998, 246:570-577
[21]Soderling SH, Bayuga SJ, Beavo JA. Indentificiation and characterization of a novel family of cyclic nucleotide phosphodiesterases[J] Biol Chem,1998, 273:15553-15558
[22]Loughney K, Snyder PB, Uher L, et al. Isolation and characterization of PDE10A, a novel human 3'～5'-cyclic nucleotide phosphodiesterases[J]. Gene,1999. 234:109-117
[23]Houslary MD, Milligan G. Tailoring cAMP-signalling response through isoform multiplicity[J]. Trends Biochem Sci,1997,22:217-224
[24]Fink TL, Francis SH, Beasley A, et al. Expression of an active, monomeric catalytic domain of the cGMP-binging cGMP-specific phosphodiesterase(PDE5)[J]. J Biol chem,1999,274:34613-34620
[25]Degerman E, Belfrage P, Manganiello VC. Structure, Localization, and regulation of cGMP-inhibited phosphodiesterase(PDE3)[J]. J Biol chem,1997,272:6823-6826
[26]Geoffroy V, Fouque F, Nivet V, et al. Activation of a cGMP-stimulated cAMP phosphodiesterase by protein kinase C in a liver Golgi-endosomal fraction[J]. Eur J Biochem,1999,259:892-900
[27]Wang H, Robinson H, Ke H[J]. J Mol Biol,2007,371:302
[28]Souness JE. Immunopharmaeology[M],2000,47:127
[29]Bumouf Pruniaux. Current Pharmaceutical Design[M],2002,8:12-55
[30]HouslayMD, Schafer P, Zhang KY. Drug Discov Today[M],2005,10:1503
[31]HouslayMD. Prog Nucleic Acids[J].Res Mol Biol,2001.69:249
[32]Nemoz G, Zhang R, Sette C, et al. Indentification of cyclic AMP- phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells[J]. FEBS Lett,1996,384:97-102
[33]Bolfer GB, Erdogan S, Jones RE, et al. characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene[J]. Biochem J,1997,328(Pt2):539-548
[34]Miro X, Casacuberta JM, Gutierrez-Lopez MD, et al. phosphodiesterases 4D and 7A splice variants in the response of HUVEC cells to TNF-alpha(1)[J]. Biochem Biophys Res Commun,2000,274:415-421
[35]Le Jeune IR, Shepherd M, Van Heeks G, et al. Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterases 4D5 in human airway smooth muscle cell. Identification and characterization of a novel PDE4D5 promoter[J]. J Bio Chen, 2002,277:35980-35989
[36]Dudai Y, Jan YN, Byers D, et al. dunce, a mutant of Drosophila deficient in learning[J]. Pro Natl Aci USA,1976,73:1684-1688
[37]Jin SL, Richard FJ, Kuo WP, et al. impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice[J]. Proc Natl Acad Sci USA,1999, 96:11998-12003
[38]Hansen G, Jin S, Umetsu DT, et al. Absence of muscarinic cholinergic airway response in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D[J]. Proc Natl Acad Sci USA,2000,97:6751-6756
[39]Iona S, Cuomo M, Bushnic T, et al. Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterase:indentification and differential expression of immunologically distinct forms in the rat brain[J].Mol pharmacol.1938;53(1):23-32
[40]Teixeira MM,Gristwood RW,Cooper N, et al. Phosphodiesterase(PDE)4 inhibitors:anti-inflammatory drugs of the future[J].Trends Pharmacol Sci.1997, 18:164-171
[41]Barnette MS, Bartus JQ, Burman M, et al. Association of the anti-inflammatory activity of phosphodicstcrase4(PDF4)inhibitors with either inhbition of PDE4 catalytic activity or competition for 3H rolipram binding[J]. Biochem Pharmacol, 1996,51:949-956.
[42]Barrette MS, Christensen SB, Essayan DM, et al. SB 207499(Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor:in vitro anti-inflammatory actions[J]. J Pharmacol Exp Ther,1998,284:420-426
[43]Houslay MD. PDE4 cAMP-specific phosphodiesterases[J]. Prog Nucleic Acid Res Mol Biol,2001,69:249-315
[44]Lim J, Pahlke G, ContiM. Activation of the cAMP-spe-cific phosphodiesterase PDE4D3 by phosphorylation. Identification and function of an inhibitory domain[J]. J Biol Chem,1999,274:19677-19685
[45]MacKenzie SJ, Baillie GS, McPhee I, et al. ERK2 mito-gen-activated protein kinase binding, phosphorylation and regulation of PDE4D cAMP specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminalUCR regions[J]. J Biol Chem,2000,275:16609-16617
[46]Gretarsdottir S, Sveinbjomsdottir S, Jonsson HH, et al. LocaliZation of a susceptibility gene for common forms of stroke to 5q12[J]. Am J Hum Genet,2002, 70:593-603
[47]Gretarsdottir S, Sveinbjomsdottir S, Thorleifsson G, Reynisdottir ST, et al. The gene encording phosphodiesterase 4D confers risk of ischemic stroke[J]. Nat genet,2003, 35:131-138
[48]Lohmussaar E, Gschwendtner A, Mueller JC, et al. ALOX5AP gene and the PDE4D gene in central European population of stroke patients[J]. Stroke,2005,36:731-736
[49]Bevan S, Porteous L, Sitzer M, et al.13Phosphodiesterase 4D gene, ischemic stroke, and asymptomatic carotid atherosclerosis[J]. stroke,2005,36:949-953
[50]Zee RY, Brophy VH, Cheng S, et al. polymorphisms of the PhosPhodiesterase 4D cAMP-specific(PDE4D)gene and risk of ischemic stroke:a Prospective nested case-control evaluation[J]. Stroke,2006,37:2012-2017
[51]Mesehia JF, Brott Tq, BrownRD Jr, et al.14 PhosPhodiesterase 4D and 5-liPoxygenase activating Protein in ischemic stroke[J]. Ann Neurol,2005, 58:351-361
[52]Woo D, Kaushal R, Kissela B, et al,5 Association of phosphodiesterase 4D with ischemic stroke:a population-based case-control study[J]. Stroke,2006,37:371-376
[53]Saleheen D, Bukhari S, Haider SR, et al.3 Association of phosphodiesterase 4D gene with ischemic stroke in a Pakistani population[J]. Stroke,2005,36:2275-2277
[54]Song Q, Cole JW, O'Connell JR, et al.12Phosphodiesterase 4D polymorphisms and the risk of cerebral infarction in a biracial population:the Stroke Prevention in young Women Study[J]. Hum Mol Genet,2006,15:2468-2478
[55]Nakayama T, Asai S, Sato N, et al. Genotype and haplotype association study of the STAK1 region on 5q 12 among Japanese[J]. Stroke,2006,37:69-76
[56]李才明,张成,张鸿炼,等.磷酸二酯酶4D基因与缺血性卒中的遗传易患性研究[J].中华神经科杂志,2006.39：180-183
[57]徐波,邓春艳,张彩英.医药世界[M],2007,2：55
[58]徐淑兰,磷酸二酯酶4D基因多态性与缺血性脑血管病的关系[J],临床神经病学杂志,2008,04：249-252
[59]孔祥丽,张祥,等.磷酸二酯4D单核苷酸多态性与脑卒中相关性研究[C].2009年微循环与血流变学基础研究及临床应用学术研讨会论文,2009,70-75.
[60]徐淑兰,张颖冬.磷酸二酯酶4D基因与缺血性脑血管病的研究进展[J].中国脑血管病杂志,2008,5：139
[61]Bevan S, Porteous L, Sitzer M, et al. Phosphodiesterase 4D gene, ischemic stroke, and asymptomatic carotid atherosclerosis[J]. Stroke,2005,369(5):949-953
[62]Greenberg SM, Rosand J. The phosphodiesterase puzzle-box:PDE4D and stroke[J]. Ann Neurol,2005,58:345-346
[63]Giorgi M, Modica A, Pompili A, et al. The induction of cyclic nucleotide phosphodiesterase 4 gene(PDE4D)impairs memory in a water maze task[J]. Behav Brain Res,2004,154:99-106
[64]Ross OA, Worrall BB, Meschia JF. CurrDrug Targets[M],2007,8:8-50
[65]Alerts MJ. Phosphodiesterase 4D poly-morphisms and the risk of cerebral infarction in a biracial population[J]. Stroke,2004,35:342-349
[2]李忠.缺血性脑血管疾病[M].北京：科学技术出版社,2002
[3]Gillum RF. The epidemiology of stroke in Native Americans[J]. Stroke,1995, 26:514-521
[4]Thom TJ. Stroke mortality trends:an international perspective[J]. Ann Epidemiol, 1993,3:509-518
[5]Lanska DJ. Geographic distribution of stroke mortality in the united states:1939-1941 to 1979-1981[J]. Neurology,1993,43:1839-1851
[6]HollowayRG, WitterDMJr, LawtonKB, et al. Inpatient costs of specific cerebrovascular events at five academic medical centers[J]. Neurology,1996, 46:854-860
[7]王文志.应高度重视和加强对脑卒中的一级预防[J].中国现代神经疾病杂志,2006,6(1)：1-2.
[8]王化文,赵冬,吴桂贤.等.北京市1984-1999年人群脑卒中发病率变化趋势分析[J].中华流行病学杂志,2001.22：269-272
[9]李振三,杨期东,苏启庚,等.我国脑卒中的地理分布[J].中华神经外科杂志,1989.5增刊：11-14
[10]谢财忠,唐军凯脑血管疾病的多重危险因素：研究与进展[J].中国临床康复2004,8(34)：7765-7767
[11]孙文萍 黄强 万琪 脑血管病的遗传研究现况[J].国外医学神经病学神经外科学分册2002,29(2)：125-128
[12]蒲传强,郎森阳,吴卫平.脑血管病学.人民军医出版社,1999,第一版,166-167
[13]Brass L, Isaacsohn J, Merikangas K, et al. Steady of twiws and strike[J]. Stroke. 1992,23:221-223.
[14]Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke[J]. Stroke,2004,35:212-227
[15]Graffagnino C, Gseck A, Doing G, et al. The importance of family history in cereb-rovascular disease[J]. Stroke.1994,25:1599～1604
[16]Brass L, Isaacsohn J, Merikangas K, et al. Steady of twiws and strike[J]. Stroke. 1992,23:221-223
[17]Couderc R, Mahieux F, Balilleul S, Fenelon G, Mary R, Fermanian J. Prevalence of apolipoprotein E phenotypes in ischemic cerebrovscular disease：a case-control study[J]. Stroke,1993,24:661-664
[18]Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease[J]. Blood,2000,95(5):1517-1531
[19]Yoshida H, Imaizumi T, Fujimoto K. A mutation in plasma platelet-activating factor acetylhydrolase(Va1279-Phe)is a genetic risk factor for cerebral hemorrhage but not for hypertention[J]. Thromb Haemost,1998,80(3):372-375
[20]Perry LJ. Homocysteine and risk of stroke[J]. J Cardiovasc Risk,1999,6(4):235-240.
[21]Perna AF, Castaldo P, Ingrosso D. Homocysteinc, a new cardiovascular risk factor, is also a powerful uremic toxin[J]. J nephrol,1999,12(4):230-240
[22]Fle A, Gaetani E, Papaleo P, et al. Proin ammatory genetic proles insubjects with history of ischemic stroke[J]. Stroke,2004,35:2270-2275
[23]Greisenegger S, Endler G, Haering D, et al. The(174)G/C polymorphism in the interleukin-6 gene is associated with the severity of acute cerebrovascularevents[J]. Thromb Res,2003,110:181-186
[24]Bulut D, Potthast R, Haneefld C, et al. ImPaired vasodilator responses to atrial natriuretic peptide in essential hypertension[J]. Eur J Clin invest,2003, 33(7):567-573
[25]王亚萍,牛小麟.基因多态性的研究方法及其临床应用[J].临床医学,2003,23(9)：49-50
[26]Gretarsdottir S, Thorleifsson G, Reynisdottir ST, et al. The gene encoding phospho-diesterase 4D confers risk of ischemic stroke[J]. Nat Genet,2003,35:131-138
[27]张颖冬.2006年卒中遗传学研究进展[J].中国卒中杂志,2007,2：136-139
[28]Kostic MM, Erdogan S, Rena G, et al. Altered expression of PDE1 and PDE4D cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin preconditioned rat heart[J]. J Mol Cell Cardiol,1997,29:3135-3146
[29]Houslay MD, Adams DR, PDE4 cAMP phosphodiesterase:modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization[J]. Biochem J,2003,370:1-18
[30]Shepherd MC, Baillie GS, StirlingD I, et al. Remodelling of the PDE4 cAMP phosphodiesterase isoform p rofile upon monocyte2macrophage differentiation of human U937 cells[J]. Br J Pharmacol,2004,142:339-351
[31]Le Jeune IR, ShepherdM, Van Heeke G, et al. Cyclic AMP2dependent transcrip tional up2regulation of phosphod2 iesterase 4D5 in human airway smooth muscle cells. Iden-tification and characterization of a novel PDE4D5 promoter[J]. J Biol Chem, 2002,277:35980-35989
[32]Wang D, Deng C, Bugaj2Gaweda B, et al. Cloning and characterization of novel PDE4D isoforms PDE4D6 and PDE4D7[J]. Cell Signal,2003,15:883-891
[33]中华神经科学会中华神经外科学会.各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29：379-380
[34]Chow dhury AH, Yokoyama T, Kokubo Y, et al. ApolipoproteinE genet ic polymorph ism and st roke subt ypes in a Bangladeshi hospital based study[J]. Epidemiol,2001, 11(3):131-138
[35]Kokubo Y, Chow dhury AH, Dat e C, et al. Age dependent associaton of apolipoprotein E genot ypes w ith stroke subt ypes in a Japanese rural population[J]. Stroke,2000,31(6):1299-1306
[36]Jin ZQ, Fan YS, Ding J, et al. Association of apolipoprotein E4 polymorphism w- ith cerebral infarction in Chinese Han population[J]. Act a Pharmacol Sin,2004, 25(3):352-356
[37]Um JY, Moon KS, Lee KM, et al. Polymorphism of angiotensin converting enzyme, angiot ensinogen, and apolipoprotein E genes in Korean patients with cerebral infarction[J]. Mol Neurosci,2003,21(1):23-28
[38]Okamoto K, Takai S, Sasaki S, et al. Trandolapril reduces infarction area after middle cerebral artery occlusion in rats[J]. Hypertens Res,2002,25:583- 588
[39]Morisaw a T, Kishimot o Y, Kitano M, et al. Inf luence of angiotensin type 1 receptor polymorphism on hypertension in patients with hyperchdolest erolemia[J]. Clin Chim Act a,2001,304:91- 97
[40]Aalt o K, Palomzi H, Miett inen H. Genetic risk factors and ischemic cerebrovacular disease:role of common varivation of the genes endoing apolipoprot- eins and angiotensin converting enzyme[J]. Ann Med,1998,30(2):224
[41]Catto A, Barrett H, Angiot ensin-converting enzyme insertion deletion polymorphism and cerebrovascular disease[J]. Stroke,1998,27:435
[42]Baroni MG, Berni A, Romeo S, et al. Genetic study of common variants at the Apo E, ApoAⅠ, ApoCⅢ, ApoB, lipoprotein lipase(LPL)and hepatic lipase(LIPC)genes and coronary artery disease(CAD):variation in LIPC gene associates with clinical out comes in patients with established CAD[J]. BMC Med Genet,2003,4:8
[43]Shimo- Nakanishi Y, Urabe T, Hat tori N, et al. Polymorphism of the lipoprotein lipase gene and risk of atherothrombotic cerebral infarction in the Japanese[J]. St -roke,2001,32:1481- 1486
[44]Moennig G, Wiebusch H, Enbergs A, et al. Detection of missense mutations in th -e genes for lipoprotein lipase and hepatic triglyceride lipase in patients with dys lipidemia undergoing coronary angiogra- phy[J]. Athcrosclerosis,2000,149:395-401
[45]Spence JD, Ban MR, Hegele RA. Lipoprot einlipase(LPL)gene variation and progression of carotid artery plaque[J]. S troke,2003,34:1176-1180
[46]Wittrup HH, Nordestgaard BG, Sillesen H, et al. A common mutation in lipoprot einlipase confers a 2-fold increase in risk of ischemic cerebrovascular disease in w-omen but not in men[J]. Circulation.2000,101:2393- 2397
[47]Morrison AC, Ballantyne CM, Bray M, et al. LPL polymorphism predicts stroke risk in men[J]. Genet Epidemiol,2002,22:233- 242
[48]Pras H, Philip H, Nitricoxide as modulat or of function[J]. Prog Neuronal,2004, 64:51- 68
[49]Dudzinski DM, Lgarashi J, Greif D, et al. The regulation and pharmacology enclothelial nitricoxide synthase[J]. Annu Rer Pharmacol Toxicol,2006,46:235- 276
[50]Hou L, Osei Hyiaman D, Yu H, et al. Association of a 27- bp repeat polym -orphism in eNOS gene with ischemic stroke in Chinese patients[J]. Neurology,2001, 56(4):490- 496
[51]Elbaz A, Poirier O, Moulin T, et al. Associatition between the Glu298Asp polymorphism in the endothelial constitutive nitric oxide synthase gene and brain in farction.[J]. St roke,2000,31(7):1634- 1639
[52]马学玲,王晓明,张桂茹,等.β纤维蛋白原基因Bcl2I多态性与血浆纤维蛋白原水平及脑梗死相关性研究[J].中国实验诊断学,2006,10(2)：153-155
[53]赵伟佳,杨和平,沈岳飞,等.脑梗死患者纤维蛋白原、血液流变学动态变化与β2纤维蛋白原基因2455G/A多态性的关系[J].中国临床康复,2005,9(5)：94-96
[54]李永杰,霍阳,高旭光,等.纤维蛋白原β基因148C/T及亚甲基四氢叶酸还原酶基因677C/T多态性与脑梗死的关系研究[J].中国神经免疫学和神经病学杂志,2005,12(6)：363-368
[55]唱浩,曹晓伟,侯迎秋,等.纤维蛋白原Bβ链2854G/A、Bcl21B1/B2基因多态性与脑梗死类型关系研究[J].临床荟萃,2005,20(22)：1268-1272
[56]Giacconi R, Cipriano C, Aibanese F, et al. The-174G/C polymorphism of IL-6 is useful to screen old subjects at risk for atherosclerosis or to reach successful ageing[J]. Exp Geront ol,2004,39:621- 628
[57]Bruunsgaard H, Christitmsen L, Pedcrsen AN, et al. The IL- 6- 174G>C polymorphism is associated with cardiovascular diseases and mortality in 80-years old humans[J]. Exp Gerontol,2004,39:255- 261
[58]宋冬晶,陈家俊,邬英全,等.IL-6 基因多态性与短暂性脑缺血发作的关系[J].吉林大学学报(医学版),2005,31(6)：924-926
[59]郭淮莲,蔡转,于步润.梗塞与HLA2 Ⅰ、Ⅲ单体型关联性初步研究[J].同济医科大学学报,1994,23(4)：280-283
[60]MeCann S K, Dusting G J, Roulston C L. Early increase of Nox4 NADPH oxidase and super oxide generation following endothelin-1-induced stroke in conscious rats[J]. J N eurosc(?) Res,2008,86(11):2524-2534
[61]杨惠玲.高级病理学[M].北京：科学出版社,1998：24-38
[62]先雄斌,袁琼兰.缺血性脑血管病的研究进展[J].海南医学,2008,19(1)：131-134
[63]Terao Y, Ohta H, Oda A, et al. Macrophage inflammatory protein-3alpha plays a key role in the inflammatory cascade in rat focal cerebral ischemia[J], N eurosci Res, 2009,64(1):75-82
[64]Dai H B, Fu Q L, ShenY, et al. The histamine H3 receptor antagonist clobenp rop it enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons[J]. Eur J Pharm-acol,2007,563(1/3):117-123
[65]Kilic E, Kilic U, Matter CM, et al. Aggravation of Focal Cerebral Ischemia by Tissue Plasminogen Activator Is Reversed by 32Hy2 droxy232Methylglutaryl Coenzyme A Reductase Inhibitor but Does Not Depend on Endothelial NO Synthase[J].Stroke, 2005,36(2):332-336
[66]MacManus JP, Linnik MD.Gene expression induced by cerebral ischemia:anapoptotic perspective[J]. Cereb Blood Flow Metab,1997,17(8):815-832. 26(7);1252-1258
[67]Sharp FR, Lu A, Tang Y, et al. Multiple molecular penumbras after focal cerebral ischemia[J]. J Cereb Blood FlowMetab,2000,20:10-11
[68]Hossmann, KA. Periin farct depolarizations. Cerebrovasc[J]. Brain Metab. Rev, 1996(8):195-208
[69]Mies G, Iijima T, Hossmann KA. Correlation between peri-infarct DC shifts and ischaemic neuronal damage in rat[J]. Neuroreport,1993, (4):709-711
[70]Gretarsdottir S, Sveinbjomsdottir S, Jonsson HH, et al. LocaliZation of a susceptibility gene for common forms of stroke to 5q12[J]. Am J Hum Genet,2002, 70:593-603
[71]Gretarsdottir S, Sveinbjomsdottir S, Thorleifsson G, Reynisdottir ST, et al. The gene encording phosphodiesterase 4D confers risk of ischemic stroke[J]. Nat genet,2003, 35:131-138
[72]Wang H, Robinson H, Ke H[J]. J Mol Biol,2007,302:371
[73]Souness JE. Immunopharmaeology[M],2000,47:127
[74]Bumouf Pruniaux. Current Pharmaceutical Design[M],2002,8:12-55
[75]Houslay MD, Schafer P, Zhang KY. Drug Discover Today[M],2005,101:503
[76]Houslay MD. Prog Nucleic Acids [J].ResMol Biol,2001,69:249.
[77]徐淑兰,张颖冬.磷酸二酯酶4D基因与缺血性脑血管病的研究进展[J].中国脑血管病杂志,2008,139-142
[78]Song Q, Cole JW, O'Connell JR, et al.12Phosphodiesterase 4D polymorphisms and the risk of cerebral infarction in a biracial population:the Stroke Prevention in young Women Study[J]. Hum Mol Genet,2006,15:2468-2478
[79]Saleheen D, Bukhari S, Haider SR, et al.3Association of phosphodiesterase 4D gene with ischemic stroke in a Pakistani population[J]. Stroke,2005,36:2275-2277
[80]Banerjee I, Grupta V, Ahmed T, et al. Inflammatory system gene polymorphism and the risk of stroke:A case-control study in an Indian population[J]. Brain Res Bull, 2008,75:158-165
[81]Nakayama T, Asai S, Sato N, et al.8 Genotype and haplotype association study of the STRK1 region on 5q12 among Japanese:a case-control study[J]. Srtoke,2006, 37:69-76
[82]Song Q, Cole JW, OpConnell JR, et al. Phosphodiesterase 4D poly-morphisms and the risk of cerebral infarction in a biracial population:the stroke prevention in young women study[J]. Hum Mol Genet,2006,15:2468
[83]曹军,洪震,黄茂盛,等.上海脑卒中急性期死亡的流行病学研究[J].中国临床神经科学,2001,9(4)：338-340
[84]徐淑兰,磷酸二酯酶4D基因多态性与缺血性脑血管病的关系[J].临床神经病学杂志,2008,04：249-252
[85]Willoughby D, WongW, Schaack J. Phosphodiesterase 4D poly-morphisms and the risk of cerebral infarction in a biracial population[J]. EMBO J,2006,25:51.
[86]Meschina JF, Brott TG, Brown RD J r, et al. Inflammatory system gene polymorphism and the risk of stroke [J].Ann Neurol,2005,51:58
[87]Woo D, Kaushal R, Kissela B, et al. phosphodiesterase 4D poly-morphisms and the risk of cerebral infarction in a biracial population[J].Stroke,2006,37:41
[88]徐波,邓春艳,张彩英.医药世界[M].2007,2：55
[89]谢财忠,唐军凯 脑血管疾病的多重危险因素：研究与进展[J].中国临床康复2004,8(34)：7765-7767
[90]全军脑血管病流调协作组.全国脑血管病学术座谈会论文专辑[C].1990.45-39
[91]李茂文,邓剑.脑栓塞患者血脂、高低密度脂蛋白载脂蛋白A、B的观察[J].卒中与神经疾病,1998,5(3)：162-164
[1]李忠.缺血性脑血管疾病[M].此京：科学技术出版社,2002：126-1 30
[2]王文志.应高度重视和加强对脑卒中的一级预防.中国现代神经疾病杂志[J].2006,6(1)：1-2
[3]Brass L, Isaacsohn J, Merikangas K, et al. Steady of twiws and strike[J]. Stroke. 1992,23:221-223
[4]Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke[J]. Stroke,2004,35:212-227
[5]Graffagnino C, Gseck A, Doing G, et al. The importance of family history in cereb-rovascular disease[J]. Stroke.1994,25:1599～1604
[6]Brass L, Isaacsohn J, Merikangas K, et al. Steady of twiws and strike[J]. Stroke. 1992,23:221-223
[7]Couderc R, Mahieux F, Balilleul S, Fenelon G, Mary R, Fermanian J. Prevalence of apolipoprotein E phenotypes in ischemic cerebrovscular disease:a case-control study[J]. Stroke,1993,24:661-664
[8]Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease[J]. Blood,2000,95(5):1517-1531
[9]Yoshida H, Imaizumi T, Fujimoto K. A mutation in plasma platelet-activating factor acetylhydrolase(Val279-Phe)is a genetic risk factor for cerebral hemorrhage but not for hypertention[J]. Thromb Haemost,1998,80(3):372-375
[10]Perry LJ. Homocysteine and risk of stroke[J]. Cardiovasc Risk,1999,6(4):235-240
[11]Perna AF, Castaldo P, Ingrosso D. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin[J]. J nephrol,1999,12(4):230-240
[12]Fle A, Gaetani E, Papaleo P, et al. Proin ammatory genetic proles insubjects with history of ischemic stroke[J]. Stroke,2004,35:2270-2275
[13]Greisenegger S, Endler G, Haering D, et al. The(174)G/C polymorphism in the interleukin-6 gene is associated with the severity of acute cerebrovascularevents[J]. Thromb Res,2003,110:181-186
[14]Cobbs CS, chen J, Greenberg DA, et al. Vascular endothelial growth factor expression in transient focal cerebral ischemia in the rat[J]. Neurosci Lett,1998, 249:79-82
[15]Markus HS, Alberts MJ. Update on genetics of stroke and cerebrovascular disease 2005[J]. Stroke,2006,37:288-290
[16]Gretarsdottir S, Thorleifsson G, Reynisdottir ST, et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke[J]. Nat Genet,2003, 35:131-138
[17]张颖冬.2006年卒中遗传学研究进展[J].中国卒中杂志,2007,2：1362139
[18]Soderiing SH, Bayuga SJ, Beavo JA. Isolation and characterization of a dual-substrate Phosphodiesterase gene family:PDE10A[J]. Pro Natl Acad SciUSA, 1999,96:7071-7076
[19]Beavo JA, Reifsnyder DH. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors[J]. Trends pharmacol Sci,1990, 11:150-155
[20]Fisher DA, smith JF, Pillar JS, et al. Isolation and characterization of PDE4A a novel human cAMP-specific phosphodiesterase[J]. Biochem Biophys Res Common,1998, 246:570-577
[21]Soderling SH, Bayuga SJ, Beavo JA. Indentificiation and characterization of a novel family of cyclic nucleotide phosphodiesterases[J] Biol Chem,1998, 273:15553-15558
[22]Loughney K, Snyder PB, Uher L, et al. Isolation and characterization of PDE10A, a novel human 3'～5'-cyclic nucleotide phosphodiesterases[J]. Gene,1999. 234:109-117
[23]Houslary MD, Milligan G. Tailoring cAMP-signalling response through isoform multiplicity[J]. Trends Biochem Sci,1997,22:217-224
[24]Fink TL, Francis SH, Beasley A, et al. Expression of an active, monomeric catalytic domain of the cGMP-binging cGMP-specific phosphodiesterase(PDE5)[J]. J Biol chem,1999,274:34613-34620
[25]Degerman E, Belfrage P, Manganiello VC. Structure, Localization, and regulation of cGMP-inhibited phosphodiesterase(PDE3)[J]. J Biol chem,1997,272:6823-6826
[26]Geoffroy V, Fouque F, Nivet V, et al. Activation of a cGMP-stimulated cAMP phosphodiesterase by protein kinase C in a liver Golgi-endosomal fraction[J]. Eur J Biochem,1999,259:892-900
[27]Wang H, Robinson H, Ke H[J]. J Mol Biol,2007,371:302
[28]Souness JE. Immunopharmaeology[M],2000,47:127
[29]Bumouf Pruniaux. Current Pharmaceutical Design[M],2002,8:12-55
[30]HouslayMD, Schafer P, Zhang KY. Drug Discov Today[M],2005,10:1503
[31]HouslayMD. Prog Nucleic Acids[J].Res Mol Biol,2001.69:249
[32]Nemoz G, Zhang R, Sette C, et al. Indentification of cyclic AMP- phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells[J]. FEBS Lett,1996,384:97-102
[33]Bolfer GB, Erdogan S, Jones RE, et al. characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene[J]. Biochem J,1997,328(Pt2):539-548
[34]Miro X, Casacuberta JM, Gutierrez-Lopez MD, et al. phosphodiesterases 4D and 7A splice variants in the response of HUVEC cells to TNF-alpha(1)[J]. Biochem Biophys Res Commun,2000,274:415-421
[35]Le Jeune IR, Shepherd M, Van Heeks G, et al. Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterases 4D5 in human airway smooth muscle cell. Identification and characterization of a novel PDE4D5 promoter[J]. J Bio Chen, 2002,277:35980-35989
[36]Dudai Y, Jan YN, Byers D, et al. dunce, a mutant of Drosophila deficient in learning[J]. Pro Natl Aci USA,1976,73:1684-1688
[37]Jin SL, Richard FJ, Kuo WP, et al. impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice[J]. Proc Natl Acad Sci USA,1999, 96:11998-12003
[38]Hansen G, Jin S, Umetsu DT, et al. Absence of muscarinic cholinergic airway response in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D[J]. Proc Natl Acad Sci USA,2000,97:6751-6756
[39]Iona S, Cuomo M, Bushnic T, et al. Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterase:indentification and differential expression of immunologically distinct forms in the rat brain[J].Mol pharmacol.1938;53(1):23-32
[40]Teixeira MM,Gristwood RW,Cooper N, et al. Phosphodiesterase(PDE)4 inhibitors:anti-inflammatory drugs of the future[J].Trends Pharmacol Sci.1997, 18:164-171
[41]Barnette MS, Bartus JQ, Burman M, et al. Association of the anti-inflammatory activity of phosphodicstcrase4(PDF4)inhibitors with either inhbition of PDE4 catalytic activity or competition for 3H rolipram binding[J]. Biochem Pharmacol, 1996,51:949-956.
[42]Barrette MS, Christensen SB, Essayan DM, et al. SB 207499(Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor:in vitro anti-inflammatory actions[J]. J Pharmacol Exp Ther,1998,284:420-426
[43]Houslay MD. PDE4 cAMP-specific phosphodiesterases[J]. Prog Nucleic Acid Res Mol Biol,2001,69:249-315
[44]Lim J, Pahlke G, ContiM. Activation of the cAMP-spe-cific phosphodiesterase PDE4D3 by phosphorylation. Identification and function of an inhibitory domain[J]. J Biol Chem,1999,274:19677-19685
[45]MacKenzie SJ, Baillie GS, McPhee I, et al. ERK2 mito-gen-activated protein kinase binding, phosphorylation and regulation of PDE4D cAMP specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminalUCR regions[J]. J Biol Chem,2000,275:16609-16617
[46]Gretarsdottir S, Sveinbjomsdottir S, Jonsson HH, et al. LocaliZation of a susceptibility gene for common forms of stroke to 5q12[J]. Am J Hum Genet,2002, 70:593-603
[47]Gretarsdottir S, Sveinbjomsdottir S, Thorleifsson G, Reynisdottir ST, et al. The gene encording phosphodiesterase 4D confers risk of ischemic stroke[J]. Nat genet,2003, 35:131-138
[48]Lohmussaar E, Gschwendtner A, Mueller JC, et al. ALOX5AP gene and the PDE4D gene in central European population of stroke patients[J]. Stroke,2005,36:731-736
[49]Bevan S, Porteous L, Sitzer M, et al.13Phosphodiesterase 4D gene, ischemic stroke, and asymptomatic carotid atherosclerosis[J]. stroke,2005,36:949-953
[50]Zee RY, Brophy VH, Cheng S, et al. polymorphisms of the PhosPhodiesterase 4D cAMP-specific(PDE4D)gene and risk of ischemic stroke:a Prospective nested case-control evaluation[J]. Stroke,2006,37:2012-2017
[51]Mesehia JF, Brott Tq, BrownRD Jr, et al.14 PhosPhodiesterase 4D and 5-liPoxygenase activating Protein in ischemic stroke[J]. Ann Neurol,2005, 58:351-361
[52]Woo D, Kaushal R, Kissela B, et al,5 Association of phosphodiesterase 4D with ischemic stroke:a population-based case-control study[J]. Stroke,2006,37:371-376
[53]Saleheen D, Bukhari S, Haider SR, et al.3 Association of phosphodiesterase 4D gene with ischemic stroke in a Pakistani population[J]. Stroke,2005,36:2275-2277
[54]Song Q, Cole JW, O'Connell JR, et al.12Phosphodiesterase 4D polymorphisms and the risk of cerebral infarction in a biracial population:the Stroke Prevention in young Women Study[J]. Hum Mol Genet,2006,15:2468-2478
[55]Nakayama T, Asai S, Sato N, et al. Genotype and haplotype association study of the STAK1 region on 5q 12 among Japanese[J]. Stroke,2006,37:69-76
[56]李才明,张成,张鸿炼,等.磷酸二酯酶4D基因与缺血性卒中的遗传易患性研究[J].中华神经科杂志,2006.39：180-183
[57]徐波,邓春艳,张彩英.医药世界[M],2007,2：55
[58]徐淑兰,磷酸二酯酶4D基因多态性与缺血性脑血管病的关系[J],临床神经病学杂志,2008,04：249-252
[59]孔祥丽,张祥,等.磷酸二酯4D单核苷酸多态性与脑卒中相关性研究[C].2009年微循环与血流变学基础研究及临床应用学术研讨会论文,2009,70-75.
[60]徐淑兰,张颖冬.磷酸二酯酶4D基因与缺血性脑血管病的研究进展[J].中国脑血管病杂志,2008,5：139
[61]Bevan S, Porteous L, Sitzer M, et al. Phosphodiesterase 4D gene, ischemic stroke, and asymptomatic carotid atherosclerosis[J]. Stroke,2005,369(5):949-953
[62]Greenberg SM, Rosand J. The phosphodiesterase puzzle-box:PDE4D and stroke[J]. Ann Neurol,2005,58:345-346
[63]Giorgi M, Modica A, Pompili A, et al. The induction of cyclic nucleotide phosphodiesterase 4 gene(PDE4D)impairs memory in a water maze task[J]. Behav Brain Res,2004,154:99-106
[64]Ross OA, Worrall BB, Meschia JF. CurrDrug Targets[M],2007,8:8-50
[65]Alerts MJ. Phosphodiesterase 4D poly-morphisms and the risk of cerebral infarction in a biracial population[J]. Stroke,2004,35:342-349